---
title: "Chuanhuan Technology released its 2024 annual performance, with a net profit attributable to the parent company of 203 million yuan, an increase of 25.15%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236826077.md"
description: "Chuanhuan Technology released its 2024 annual report, with operating revenue of 1.363 billion yuan, a year-on-year increase of 22.88%; net profit attributable to the parent company was 203 million yuan, a year-on-year increase of 25.15%. The net profit after deducting non-recurring gains and losses was 193 million yuan, a year-on-year increase of 26.31%. The basic earnings per share were 0.9347 yuan, and it plans to distribute a cash dividend of 2.77 yuan (including tax) for every 10 shares to all shareholders"
datetime: "2025-04-21T15:31:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236826077.md)
  - [en](https://longbridge.com/en/news/236826077.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236826077.md)
generator: "portal-rs"
---

# Chuanhuan Technology released its 2024 annual performance, with a net profit attributable to the parent company of 203 million yuan, an increase of 25.15%

According to the Zhitong Finance APP, Chuanhuan Technology (300547.SZ) released its annual report for 2024, showing an operating income of 1.363 billion yuan, a year-on-year increase of 22.88%. The net profit attributable to shareholders of the listed company was 203 million yuan, a year-on-year increase of 25.15%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 193 million yuan, a year-on-year increase of 26.31%. The basic earnings per share were 0.9347 yuan. In addition, it plans to distribute a cash dividend of 2.77 yuan (including tax) for every 10 shares to all shareholders

### Related Stocks

- [300547.CN](https://longbridge.com/en/quote/300547.CN.md)

## Related News & Research

- [CMA: Gross profit doubled and FY27 revenue is forecast to grow over 80% as scale and margins improve](https://longbridge.com/en/news/297444189.md)
- [Palvella completes rolling FDA NDA submission for QTORIN rapamycin in microcystic lymphatic malformations](https://longbridge.com/en/news/297509688.md)
- [Musinsa signs exclusive Malaysia distribution deal with MAP for Musinsa Standard](https://longbridge.com/en/news/297436668.md)
- [Texas Governor Abbott blocks funding for more Flock cameras](https://longbridge.com/en/news/297431096.md)
- [RUBBER-Japan futures rise on supply concerns in top producing regions](https://longbridge.com/en/news/297141554.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**